A recent study has shed light on the significant impact of the worldwide demand for a drug used to aid in weight loss on Canadian pharmacies. The drug, known as Semaglutide or Ozempic, has gained immense popularity due to its proven effectiveness in promoting weight loss. While Ozempic is approved for the treatment of type 2 diabetes, Health Canada has approved a similar drug called Wegovy specifically for weight loss.
The study, led by Dr. Cathy Balsom, a clinical pharmacist and professor at Memorial University, reveals that the high demand for Wegovy has caused an unprecedented surge in requests within Canada, leading to a significant depletion of stocks in pharmacies across the country. The situation has been further exacerbated by the shortage of Wegovy itself, as the drug’s demand in the United States has prevented Canadian pharmacies from accessing it.
As a result, pharmacists have turned to prescribing Ozempic as an alternative, amplifying the challenge of maintaining an adequate supply for patients. While Ozempic is not specifically approved for weight loss, it has become a substitute due to the unavailability of Wegovy. This has put a strain on Canadian pharmacies and has made it increasingly challenging to meet the growing demand for weight loss medications.
Q: Why is Ozempic being used as a substitute for Wegovy?
A: Due to the high demand and shortage of Wegovy, Ozempic is being prescribed as an alternative weight loss medication.
Q: Is Ozempic approved for weight loss?
A: No, Ozempic is approved for the treatment of type 2 diabetes, but it is being used off-label for weight loss due to its similarities to Wegovy.
Q: Has Canada been able to obtain a sufficient supply of Wegovy?
A: No, the demand for Wegovy in the United States has hindered Canada’s ability to access an adequate stock of the weight loss drug.